Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →You can get a GLP-1 medication for weight loss from a local clinic, retail health center, primary care office, obesity specialist, or licensed telehealth provider. Most clinicians use BMI 30, or BMI 27 with a weight-related condition, as the main eligibility screen. Options include FDA-approved medicines and, when appropriate, compounded GLP-1s from licensed 503A pharmacies [1,2,3,12].
What is a GLP-1, and why is it prescribed for weight loss?
GLP-1 receptor agonists are medicines that act like glucagon-like peptide-1, a gut hormone involved in appetite, fullness, stomach emptying, and blood-sugar signaling. Several GLP-1 or related incretin medicines are FDA-approved for chronic weight management in adults who meet label criteria [1,2,3].
Wegovy (semaglutide, a GLP-1 receptor agonist; also available as compounded semaglutide through licensed 503A pharmacies when clinically appropriate) is FDA-approved for chronic weight management and to reduce major adverse cardiovascular events in certain adults with established cardiovascular disease and obesity or overweight [1]. Zepbound (tirzepatide, a GIP/GLP-1 receptor agonist; also available as compounded tirzepatide through licensed 503A pharmacies when clinically appropriate) is FDA-approved for chronic weight management and for moderate to severe obstructive sleep apnea in adults with obesity [2]. Saxenda (liraglutide, a GLP-1 receptor agonist) is FDA-approved for chronic weight management in certain adults and adolescents [3].
In the STEP 1 trial, participants received once-weekly semaglutide 2.4 mg plus lifestyle counseling and had greater average weight loss than placebo; individual results vary [7]. In the same section of care, safety must be reviewed: the Wegovy label lists common gastrointestinal side effects and warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, and thyroid C-cell tumor risk, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 [1].
In the SURMOUNT-1 trial, participants received once-weekly tirzepatide 5 mg, 10 mg, or 15 mg plus lifestyle counseling and had greater average weight loss than placebo; individual results vary [8]. Safety review is just as important: the Zepbound label lists common side effects such as nausea, diarrhea, vomiting, and constipation, plus warnings for pancreatitis, gallbladder disease, kidney injury, low blood sugar with certain diabetes drugs, and thyroid C-cell tumor risk [2].
Where can I get a GLP-1 near me?
GLP-1 care is available through local weight-loss clinics, retail clinics, primary care, endocrinology, obesity medicine, and licensed telehealth. The best path depends on your health history, insurance, state access, pharmacy supply, and whether you need in-person exams or lab monitoring.
Local medical weight-loss clinics
Local medical weight-loss clinics may offer in-person visits, body measurements, nutrition support, and prescription evaluation. Before scheduling, ask whether a licensed clinician reviews eligibility, contraindications, side effects, follow-up, and the pharmacy used for dispensing [13,14].
Retail clinics like CVS MinuteClinic
Retail clinics may offer weight-loss visits in select locations. CVS MinuteClinic describes weight-loss services that can include evaluation, lab review when appropriate, lifestyle planning, and discussion of medication options, but services and prescribing rules can vary by state and location [13].
Primary care and endocrinology
Primary care clinicians can review blood pressure, diabetes risk, sleep apnea symptoms, current medications, pregnancy plans, and family history. Endocrinology may be useful for people with type 2 diabetes, thyroid disease, complex metabolic conditions, or prior medication side effects [14,15].
Licensed telehealth providers that ship to your state
Telehealth prescribing can be convenient when the provider is licensed in your state, reviews your medical history, and uses a pharmacy that can legally dispense to you. Some telehealth services work with licensed 503A compounding pharmacies, which prepare patient-specific compounded medications when clinically appropriate and allowed under federal and state rules [12].
Do I qualify for a GLP-1 prescription?
BMI criteria are usually the starting point: FDA weight-management labels commonly use BMI 30 or higher, or BMI 27 or higher with at least one weight-related condition. A clinician also reviews safety risks, pregnancy status, medications, and whether another treatment may be a better fit [1,2,3].
BMI thresholds: 30+, or 27+ with a comorbidity
Wegovy, Zepbound, and Saxenda labels include adults with obesity, or adults with overweight plus at least one weight-related condition, using BMI cutoffs of 30 or higher, or 27 or higher with a condition such as hypertension, type 2 diabetes, or dyslipidemia [1,2,3]. These label criteria support evaluation but do not replace clinician judgment.
Health conditions that support eligibility
Weight-related conditions can include type 2 diabetes, high blood pressure, dyslipidemia, and sleep apnea [1,2,3]. Major medical organizations recognize obesity as a chronic disease, and clinical guidelines support combining lifestyle care with medication for selected patients when expected benefits outweigh risks [14,15].
Who is not a candidate
A GLP-1 or GIP/GLP-1 medication may not be appropriate for people with certain risks. FDA labels for semaglutide and tirzepatide include a boxed warning about thyroid C-cell tumors and state that these medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; labels also warn about pancreatitis, gallbladder disease, kidney injury related to dehydration, and severe gastrointestinal symptoms [1,2].
Pregnancy plans also matter. FDA weight-loss labels state that weight loss offers no benefit during pregnancy and may cause fetal harm; the Wegovy and Zepbound labels advise stopping before a planned pregnancy, and a clinician can discuss timing and safer alternatives [1,2,3].
Which GLP-1 medications are available for weight loss?
Weight-loss GLP-1 options include FDA-approved brand medicines and, when clinically appropriate, compounded formulations. The FDA-approved Wegovy label describes a 0.25 mg once-weekly starting dose for the first 4 weeks before stepwise escalation; this is label information, not personal dosing advice [1].
| Medication or option | Drug class | FDA status for weight loss | Label or study route | Key safety notes |
|---|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 receptor agonist | FDA-approved for chronic weight management in eligible adults and certain adolescents; also approved to reduce major adverse cardiovascular events in certain adults with cardiovascular disease and obesity or overweight [1] | FDA label describes once-weekly subcutaneous injection, starting at 0.25 mg weekly for 4 weeks before stepwise escalation [1] | Nausea, vomiting, diarrhea, constipation, abdominal pain, pancreatitis warning, gallbladder warning, kidney injury risk, and thyroid C-cell tumor boxed warning [1] |
| Ozempic (semaglutide) | GLP-1 receptor agonist | FDA-approved for type 2 diabetes and cardiovascular risk reduction in certain adults with type 2 diabetes; not FDA-approved for chronic weight management [4] | FDA label describes once-weekly subcutaneous injection for diabetes dosing [4] | Weight-loss use is off-label; similar GLP-1 safety warnings apply and should be reviewed with a clinician [4] |
| Rybelsus (oral semaglutide) | GLP-1 receptor agonist | FDA-approved for type 2 diabetes; not FDA-approved for chronic weight management [6] | FDA label describes daily oral dosing for diabetes [6] | Can cause gastrointestinal side effects and carries GLP-1 class warnings [6] |
| Zepbound (tirzepatide) | GIP/GLP-1 receptor agonist | FDA-approved for chronic weight management in eligible adults and for moderate to severe obstructive sleep apnea in adults with obesity [2] | FDA label describes once-weekly subcutaneous injection, starting at 2.5 mg weekly for 4 weeks before stepwise escalation [2] | Nausea, diarrhea, vomiting, constipation, pancreatitis warning, gallbladder warning, kidney injury risk, low blood sugar risk with certain diabetes drugs, and thyroid C-cell tumor boxed warning [2] |
| Mounjaro (tirzepatide) | GIP/GLP-1 receptor agonist | FDA-approved for type 2 diabetes; not FDA-approved for chronic weight management [5] | FDA label describes once-weekly subcutaneous injection for diabetes dosing [5] | Weight-loss use is off-label; tirzepatide safety warnings should be reviewed with a clinician [5] |
| Saxenda (liraglutide) | GLP-1 receptor agonist | FDA-approved for chronic weight management in eligible adults and certain adolescents [3] | FDA label describes once-daily subcutaneous injection with dose escalation [3] | Nausea, vomiting, diarrhea, constipation, pancreatitis warning, gallbladder warning, and thyroid C-cell tumor boxed warning [3] |
| Compounded semaglutide via 503A pharmacy | GLP-1 receptor agonist active ingredient in a compounded formulation | Not an FDA-approved product; may be prescribed only when clinically appropriate and compounded under applicable law [12] | Prescription-specific; no FDA-approved compounded dosing label exists [12] | Compounded drugs do not receive FDA premarket review for safety, effectiveness, or quality; adverse effects may overlap with semaglutide [1,12] |
| Compounded tirzepatide via 503A pharmacy | GIP/GLP-1 receptor agonist active ingredient in a compounded formulation | Not an FDA-approved product; may be prescribed only when clinically appropriate and compounded under applicable law [12] | Prescription-specific; no FDA-approved compounded dosing label exists [12] | Compounded drugs do not receive FDA premarket review for safety, effectiveness, or quality; adverse effects may overlap with tirzepatide [2,12] |
| Orforglipron | Oral GLP-1 receptor agonist under study | Not FDA-approved for weight loss or diabetes based on the cited trial publication [11] | Studied as an oral medication in clinical trials [11] | Investigational; benefits, risks, and approved uses are not established by FDA labeling [11] |
In the SCALE Obesity and Prediabetes trial, participants received liraglutide 3.0 mg daily with diet and activity counseling and had greater average weight loss than placebo; individual results vary [9]. Safety issues remain central: the Saxenda label lists common gastrointestinal side effects, gallbladder events, pancreatitis warnings, and a thyroid C-cell tumor boxed warning [3].
How much does a GLP-1 cost for weight loss?
GLP-1 cost can range widely because insurance, prior authorization, pharmacy supply, savings programs, state rules, and whether the medication is brand-name or compounded all matter. Verify current pricing at the time of your visit because cash prices, coverage, and availability can change.
Cash pay vs insurance
Insurance may cover FDA-approved weight-loss medications, but many plans require prior authorization. Prior authorization means the clinician submits documentation, often including BMI, weight-related conditions, past treatments, and the specific FDA-approved indication being requested [1,2,3].
Manufacturer savings programs
Manufacturer savings programs may lower out-of-pocket costs for people who meet program rules, but they often exclude government insurance and can change. Check the official manufacturer site and your pharmacy before assuming a final price [16,17].
Compounded GLP-1 pricing
Compounded semaglutide and compounded tirzepatide are not FDA-approved products, and they are not the same as FDA-approved brand pens. When clinically appropriate, a licensed clinician may prescribe a patient-specific compounded medication from a licensed 503A pharmacy; the FDA states that compounded drugs do not undergo FDA premarket review for safety, effectiveness, or quality [12].
In-person clinic vs online telehealth: which is right for me?
Telehealth prescribing may fit if you want remote visits, home delivery where allowed, and routine follow-up without driving to a clinic. In-person care may be better if you need a physical exam, complex lab work, injection teaching, or closer monitoring.
| Care option | May be a good fit if | Limitations to ask about |
|---|---|---|
| Local weight-loss clinic | You want in-person visits, body measurements, and hands-on support | Ask who prescribes, how follow-up works, whether labs are included, and which pharmacies are used |
| Retail clinic | You want a nearby appointment and a structured weight-loss visit | Services vary by state and location; confirm medication evaluation and follow-up policies [13] |
| Primary care or endocrinology | You have diabetes, high blood pressure, thyroid disease, kidney disease, or complex medications | Appointments may take longer to schedule; coverage and prior authorization vary |
| Licensed telehealth provider | You want remote evaluation, prescription review, and shipping where allowed | Confirm state licensure, pharmacy credentials, lab requirements, emergency policies, and follow-up |
No matter which path you choose, safe care should include more than a prescription. Ask how the provider screens for contraindications, handles side effects, manages changes based on FDA-label schedules or clinical judgment, coordinates lab work, and responds if you develop severe vomiting, dehydration, abdominal pain, or symptoms of gallbladder disease [1,2,3].
How do I get started on a GLP-1 through Chia?
Chia is one licensed telehealth option for people who want a clinician-reviewed path to compounded GLP-1 treatment, when appropriate, with prescriptions sent through US 503A pharmacy partners. A typical start includes an intake form, clinician review, eligibility decision, pharmacy dispensing if prescribed, and follow-up for tolerability and progress.
A responsible evaluation should ask about BMI, weight-related conditions, current medicines, pregnancy plans, pancreatitis history, gallbladder history, kidney disease, diabetes medications, eating disorder history, and personal or family history of medullary thyroid carcinoma or MEN2. These questions matter because FDA labels include contraindications and warnings that can change whether a GLP-1 is safe for a specific person [1,2,3].
3-min quiz
See if you may be eligible
A licensed clinician can review your health history, goals, medications, and safety risks before deciding whether a GLP-1 option is appropriate.
What should I expect after my first GLP-1 prescription?
The first 4 weeks are often about tolerability and safety monitoring, not speed. FDA labels for Wegovy and Zepbound describe low once-weekly starting doses with stepwise escalation to reduce gastrointestinal side effects; a clinician decides what is appropriate for each patient [1,2].
Dose titration schedule
The FDA-approved Wegovy label starts semaglutide at 0.25 mg once weekly for 4 weeks before stepwise increases toward maintenance dosing [1]. The FDA-approved Zepbound label starts tirzepatide at 2.5 mg once weekly for 4 weeks before stepwise increases based on the label and clinical judgment [2]. These are label facts, not instructions for any individual reader.
Side effects and how they are managed
Common side effects include nausea, vomiting, diarrhea, constipation, stomach pain, and decreased appetite [1,2,3]. Serious warnings include pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar when used with insulin or sulfonylureas, and thyroid C-cell tumor risk in people with certain histories [1,2,3].
Clinicians may manage mild gastrointestinal side effects by reassessing food intake, hydration, other medications, and escalation timing. Severe or persistent abdominal pain, repeated vomiting, signs of dehydration, or symptoms of gallbladder disease should be addressed urgently with a clinician [1,2,3].
Follow-up visits and lab work
Follow-up may include weight trend, blood pressure, side effects, medication changes, and labs such as A1C, kidney function, lipids, or pregnancy testing when clinically relevant. Guidelines support long-term obesity care that combines medication, nutrition, activity, sleep, and management of related conditions [14,15].
Some telehealth providers may offer same-day or fast clinician review, but a prescription is never automatic. A licensed clinician must confirm eligibility, screen for contraindications, and decide whether medication is appropriate [1,2,3].
There is no single best GLP-1 for everyone. Trials show that semaglutide, tirzepatide, and liraglutide can support weight loss in eligible patients, but side effects, contraindications, cost, supply, insurance, diabetes status, and personal history all matter [7,8,9].
No. Wegovy is an FDA-approved semaglutide product with an FDA-reviewed label. Compounded semaglutide is patient-specific and is not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed [1,12].
No. Zepbound is an FDA-approved tirzepatide product for chronic weight management and certain adults with obesity and obstructive sleep apnea. Compounded tirzepatide is not FDA-approved and should only be considered with licensed clinician and pharmacy oversight [2,12].
Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not chronic weight management. Weight-loss use is off-label and should be discussed with a clinician who can review risks, alternatives, and coverage [4,5].
FDA weight-management labels commonly use BMI 30 or higher, or BMI 27 or higher with a weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or sleep apnea. A clinician must still decide whether the benefits outweigh the risks for you [1,2,3].
Rybelsus is oral semaglutide, but it is FDA-approved for type 2 diabetes, not chronic weight management [6]. Orforglipron is an oral GLP-1 receptor agonist being studied in trials and is not FDA-approved for weight loss based on the cited trial publication [11].
AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still must review eligibility, safety, and state availability before deciding whether treatment is appropriate.
3-min quiz
Talk with a licensed clinician
If you are considering a GLP-1, the next step is a medical evaluation that reviews eligibility, safety, cost, and follow-up.
References
- 1.Novo Nordisk. Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2024.
- 2.Eli Lilly and Company. Zepbound (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2024.
- 3.Novo Nordisk. Saxenda (liraglutide) injection prescribing information. U.S. Food and Drug Administration, 2023.
- 4.Novo Nordisk. Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration, 2025.
- 5.Eli Lilly and Company. Mounjaro (tirzepatide) injection prescribing information. U.S. Food and Drug Administration, 2024.
- 6.Novo Nordisk. Rybelsus (semaglutide) tablets prescribing information. U.S. Food and Drug Administration, 2024.
- 7.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 8.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 9.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 2015.
- 10.Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 2023.
- 11.Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. New England Journal of Medicine, 2023.
- 12.U.S. Food and Drug Administration. Compounded drugs and the FDA: questions and answers. U.S. Food and Drug Administration, 2024.
- 13.CVS Health. MinuteClinic weight loss program service information. CVS Health, 2025.
- 14.Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice, 2016.
- 15.Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 2015.
- 16.Novo Nordisk. Wegovy savings and support information. Novo Nordisk, 2025.
- 17.Eli Lilly and Company. Zepbound savings card and coverage information. Eli Lilly and Company, 2025.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
